A Phase 3 interventional study of Elacestrant + Everolimus in ER+/HER2-, ESR1mut, Advanced Breast Cancer

Recruiting Phase 3 NCT06382948

Study Description

A Study of Elacestrant and Everolimus in Patients with Advanced Breast Cancer that is Estrogen Receptor-Positive, HER2-Negative, and has an ESR1 Mutation

Study Details

Registry ID:
NCT06382948
Conditions:
Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
Phase:
Phase 3
Target Enrollment:
300 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (116 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →